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Abstract
DNA double-strand breaks are among the most serious types of DNA damage and their signaling and repair is cri-
tical for all cells and organisms. The repair of both induced and programmed DNA breaks is fundamental as
demonstrated by the many human syndromes, neurodegenerative diseases, immunodeficiency and cancer asso-
ciated with defective repair of these DNA lesions. Homologous recombination and non-homologous end-joining
pathways are the two major DNA repair pathways responsible for mediating the repair of DNA double-strand
breaks. The signaling of DNA double-strand breaks is critical for cells to orchestrate the repair pathways and main-
tain genomic integrity. This signaling network is highly regulated and involves a growing number of proteins and
elaborated posttranslational modifications including phosphorylation and ubiquitylation. Here, we highlight the
recent progress in the signaling of DNA double-strand breaks, the major proteins and posttranslational modifica-
tions involved and the diseases and syndromes associated with impaired signaling of these breaks.
Background
Mammalian cells and organisms have evolved elegant
ways to maintain their genomic integrity and respond to
the various DNA lesions that they continuously face.
DNA damage can result from exogenous stresses, such
as ionizing radiation (IR), ultraviolet (UV) light and che-
mical compounds, or from endogenous insults such as
reactive oxygen species (ROS) and DNA replication
errors [1].
DNA double-strand breaks (DSBs) are among the
most serious and lethal types of DNA damage, as a sin-
gle DSB is sufficient to kill a cell or disturb its genomic
integrity [1]. DSBs are generated in response to exogen-
ous and endogenous DNA insults. For instance, DSBs
are induced in response to oncogenic activation [2]. In
human precancerous lesions, oncogene activation has
been shown to lead to continuous formation of DNA
DSBs [3,4]. These DSBs activate the tumor suppressor
p53 that mediate apoptosis and/or senescence to
restrain the growth of the precancerous cells. In the pre-
sence of additional mutations that inactivate p53, pre-
cancerous cells become cancerous as they escape p53
mediated apoptosis and/or senescence [5,6]. In addition
to the induced DSBs, there are also programmed DSBs
that are critical for physiological processes such as
meiosis and T and B-cell receptor rearrangements [7,8].
DNA damage response (DDR) to various types of
DNA insults is a well orchestrated process and is
required to maintain genomic integrity (Figure 1) [9-12].
In response to DSBs, a signaling process activates cell
cycle checkpoints and pauses cell cycle progression, thus
granting time for damaged cells to repair their DNA
(Figure 2 and section 2s) [13]. Two major repair path-
ways for DSBs exist in mammalian cells; the homolo-
gous recombination (HR) and the non-homologous
end-joining (NHEJ) pathways [14]. The HR pathway is
error free but requires an intact homologous template
such as a sister chromatid. The NHEJ recombination
pathway is the prominent pathway for DSB repair in
mammalian cells; however this pathway is error prone
as unlike HR pathway it does not require a long homo-
logous sequence to guide the repair [15]. The choice of
HR or NHEJ pathway for repairing DSBs is dependent
on the phases of the cell cycle. HR is the main DSB
repair pathway used during the S and G2 phase when
sister chromatids are intact and readily available,
whereas NHEJ is predominant during the G1 phase of
the cell cycle [16,17].
* Correspondence: rhakem@uhnres.utoronto.ca
† Contributed equally
Ontario Cancer Institute, University Health Network and Department of
Medical Biophysics, University of Toronto, 610 University Avenue, Toronto,
M5G 2M9 Ontario, Canada
Bohgaki et al. Genome Integrity 2010, 1:15
http://www.genomeintegrity.com/content/1/1/15 GENOME INTEGRITY
© 2010 Bohgaki et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Figure 1 Mammalian DNA damage repair pathways and checkpoints. Various exogenous and endogenous sources can generate damaged
DNA. In response to DNA damage cells activate the appropriate DNA damage repair and checkpoint pathways or apoptosis. Lesions of single or
double-stranded DNA lead to the activation of cell cycle checkpoints and a number of DNA damage repair pathways including MMR (mismatch
repair), BER (base excision repair), NER (nucleotide excision repair), TLS (translesion DNA synthesis), HR (homologous recombination) and NHEJ
(non-homologous end joining). Impaired repair of damaged DNA can lead to accumulation of, mutations and genomic instability. In addition,
defective repair of damaged DNA can lead to aging as well as predisposition for various genetic diseases including cancer and
immunodeficiency.
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Page 2 of 14Figure 2 Schematic representation of the DNA damage-signaling that leads to activation of cell cycle checkpoints or apoptosis.
(A) Examples of proteins involved in the different steps of DNA damage signaling are shown. DNA lesions are recognized by sensors (e.g ATM),
and mediators (e.g 53BP1) serve to amplify the signaling of DNA damage. Next, proteins including CHK2 serve to transduce the DNA damage
signals. Finally, effectors (e.g p53) are required to trigger the appropriate DNA damage cellular responses that include apoptosis, senescence or
cell cycle arrest or delay that allow cells to repair their damaged DNA. (B) In response to DSBs and/or DNA replication failure, activated ATM
and/or ATR phosphorylate the CHK2 and CHK1. Activated ATM, ATR and CHK2 also phosphorylate p53, thus increasing its stability and activation.
Activated p53 transactivates the p21 that inhibits the cyclin-dependent-kinases and delays the G1/S transition. In the case the damage DNA is
beyond repair, p53 can promote apoptosis of the damaged cells through the transactivation of its transcriptional targets including the Bax,
Puma and Noxa. CHK1 is essential for S and G2/M checkpoints activation. CDC25C inactivation and WEE1 activation through their
phosphorylation by CHK1 result in the inhibition of CDC2/cyclin B activity and G2/M arrest. CDC25C dephosphorylates CDC2 leading to its
activation [177]. In response to DNA damage, CHK1 phosphorylates CDC25C allowing its interaction with 14-3-3 and inhibition of its phosphatase
activity [178,179]. CHK1 also phosphorylates WEE1, affecting its distribution through interaction with 14-3-3. Finally, CHK1 also phosphorylates
CDC25A leading to CDK2 inactivation and delayed intra-S phase [180].
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DSBs, DDR pathways are activated by kinases such as
ATM and ATR, thus leading to the senescence or the
death of damaged cells [18-21] (Figure 2). Failure to
detect, signal or repair DSBs, can result in damaged
cells escaping the cell cycle checkpoints and evading
death and thus these damaged cells can potentially gen-
erate a progeny that carries harmful mutations or chro-
mosomal aberrations. Such genomic instability is a key
driving force for the development of various human syn-
dromes, immunodeficiency, aging and cancer [1,9].
During the past few years, significant progress has
been made toward better understanding of the mechan-
isms underlying the DSB responses in mammalian cells.
Current data have demonstrated the importance of the
early detection and signaling of DSBs. This signaling of
DSBs has emerged as a highly regulated and complex
process. Mutations in a number of genes involved in
DSBs signaling have highlighted the importance of this
process.
In this review we will focus on proteins that have been
demonstrated to play important roles in the detection
and signaling of DSBs. We will discuss a number of
post-translational modifications (PTMs) including phos-
phorylation, ubiquitylation, SUMOylation, acetylation
and methylation, that are critical for DSBs signaling.
Mutations in a number of genes involved in the signal-
ing of DSBs have been demonstrated to lead to various
human pathologies including cancer and will be also
discussed in this review.
Signaling of DNA Double-Strand Breaks
Role of Phosphorylation and Dephosphorylation in the
Signaling of DSBs
Mammalian cells have evolved a sophisticated network of
proteins to sense and signal DSBs (Figure 3). Members of
the Phosphatidylinositol-3 kinase-related kinases (PIKK)
family play important roles in different stages of DSB sig-
naling through their ability to phosphorylate a number of
substrates leading to the propagation of DSB signaling
[22]. Members of the PIKK family consist of serine/threo-
nine protein kinases with a conserved kinase domain
(KD). PIKK family members also show conservation of
three other domains that regulate their KD activity.
These three domains are the FRAP-ATM-TRRAP (FAT)
domain, the PIKK-regulatory domain (PRD) and the
FRAP-ATM-TRRAP-C-terminal (FATC) domain
[23-25]}. The FATC domain is critical for the kinase
activity of the PIKK family members and mutations of
this domain reduce the kinase activity of PIKK family
members [23,26]. In addition, the FATC domain was
shown to serve protein-protein interactions. The C-term-
inal PRD is located between the KD and FATC domains
and is the target of posttranslational modifications.
T h r e em e m b e r so ft h eP I K Kf a m i l ya r ee s s e n t i a lf o r
the response to DSBs (Figure 2). These kinases are
Ataxia-Telangiectasia-Mutated (ATM), Ataxia Telan-
giectasia and Rad3 Related (ATR) and DNA-dependent
Protein Kinase catalytic subunit (DNA-PKcs). ATM and
DNA-PKcs are critical for the signaling of DSBs while
ATR is mainly involved in the response to DNA single
strand breaks (SSBs) and stalled replication forks
[13,22,27]. Remarkably, recent studies indicated that
these PIKKs have a large number of substrates, and
more than 900 sites of over 700 proteins have been
identified as potential phosphorylation sites for ATM
and ATR in response to DNA damage [28]. It has been
shown that when ATM activity is compromised, DNA-
PKcs can compensate to a certain degree for the defec-
tive ATM in some situations, such as V(D)J or class
switch recombination in lymphocytes [29-31]. However,
ATM, DNA-PKcs and ATR functions are all essential as
demonstrated by the association of their mutations with
a number of human syndromes discussed in section 3.
In mammalian cells, DSB ends are recognized by the
MRE11/Rad50/NBS1 (MRN) and the KU70/KU80 com-
plexes that function as sensors of DSBs but are also
involved in processing the DNA break ends [32,33]. The
MRN complex recruits ATM, while KU70/80 recruits
DNA-PKcs, to DNA lesion sites [34]. The MRE11
(Meiotic Recombination 11) protein is conserved from
archaea to mammalian cells and is involved in HR,
NHEJ and maintenance of telomeres [35]. MRE11 has
single strand endonuclease activity and 3’ to 5’ DNA
exonuclease activity. RAD50 is a homolog of the S. cere-
visiae rad50 and is a member of the structural mainte-
nance of chromosome (SMC) protein family [36]. The
third partner in the MRN complex is the NBS1 (Nijme-
gen breakage syndrome 1) protein also known as Nibrin
and p95. Interaction of MRE11 with RAD50 upregulates
both its exonuclease and endonuclease activities, while
its interaction with NBS1 upregulates only its endonu-
clease activity [37].
The MRN complex interacts with the N-terminal
domain of ATM and recruits it to DSBs. The MRN
complex is also required for ATM activation[38-41]. In
undamaged cells, ATM forms inactive dimers or multi-
mers; however, upon the formation of DSBs, ATM is
autophosphorylated on serine 1981 leading to its disso-
ciation into active monomers [25,42]. In addition to ser-
ine 1981, ATM is also autophosphorylated on serine
367 and serine 1893 and mutations of these sites reduce
its activity [25,42,43]. ATM substrates such as NBS1 are
rapidly phosphorylated following ATM autophosphory-
lation and thus ATM autophosphorylation is considered
as a hallmark for the activation of ATM [25,44]. Autop-
hosphorylation of ATM serine 1981 has been demon-
strated to be indispensable for its monomerization and
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Page 4 of 14Figure 3 Multistep signaling of DNA double-stranded breaks. ATM and ATR, through the phosphorylation of their downstream substrates,
play central roles in DSB signaling and the activation of cell cycle checkpoints. (A) Mre11/Rad50/NBS1 (MRN)-complex mainly recognizes DSBs
and undergo ATM activation. Activated ATM phophorylates multiple substrates, including H2A.X and MDC1. MDC1 recognizes g-H2A.X and bind
to it. Then RNF8 recognizes the thyreonyl-phosphorylated MDC1 via its FHA domain and is recruited to DSB sites where it ubiquitylates the
histone H2A. Subsequently, RNF168 is recruited to the ubiquitylated H2A, further ubiquitylating it with Ubc13 and likely leading to the
modification of the chromatin structure. Through its tutor domain, 53BP1 is recruited to histone H4 di-methylated on lysine 20, while RAP80 and
its protein complex are recruited to the polyubiquitylated H2A. (B) In the S and G2 phase, DSBs are recognized by the MRN-complex and CtIP is
recruited to DSBs. CtIP is phosphorylated by CDK and ATM, and is ubiquitylated by BRCA1 in response to DNA damage. Collaboration of MRN
and CtIP results in DSB end resection, and subsequently DNA2/BLM-complex and Exo1 promote further the resection of DSB ends leading to
generation of single strand DNA (ssDNA). RPA binds to the ssDNA and induces ATR activation and HR repair [181-184]. (C) Replication fork
stalling. The damaged single-stranded DNA is coated by RPA and this structure plays crucial roles in the recruitment of the helicase HARP and
the ATR-ATRIP complex to sites of DNA damage[185-187]. P: phosphorylation, Ub: ubiquitin, S: SUMOylation, ATRIP: ATR interacting protein, RPA:
Replication protein A. HARP: HepA-related protein.
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study demonstrated that ATM autophosphorylation is
not required for its initial localization to DSBs, but is
important its stabilization at the sites of DSBs [46]. The
recent finding that transgenic mice carrying alanine sub-
stituted autophosphorylation serine sites 1987, 367 and
1899 of Atm (corresponding to human ATM serine
1981, 367 and 1893) display functional Atm-dependent
responses have raised questions regarding the impor-
tance of ATM autophosphorylation for its in vivo func-
tions [47].
Three serine/threonine protein phosphatase PP2A,
PP5 and WIP1, have been implicated in the control of
ATM activation [48-50]. In undamaged cells, PP2A
interacts with ATM to ensure that ATM is not inappro-
priately activated by autophosphorylation [48]. In
response to DNA DSBs, PP2A dissociates from ATM,
therefore minimizing the risk of competition between
phosphorylation and phosphatase activities [48]. The
phosphatase WIP1 is also capable of removing phos-
phates from serine 367 and serine 1981 autophosphory-
lation sites [49], while PP5 has been shown to interact
with ATM and to upregulate its activity in response to
DNA damage [50].
In response to DNA damage, activated ATM, or alter-
natively DNA-PKcs or ATR, rapidly phosphorylates
H2A.X, a histone H2A variant, on its serine 139 (g-H2A.
X) [51]. The large number of substrates for activated
A T Mi n c l u d e sp r o t e i n ss u c ha st h es t r u c t u r a lm a i n t e -
nance of chromosome-1 (SMC1), NBS1, checkpoint
kinase 2 (CHK2), tumor protein 53 (P53), breast cancer
early onset-1 (BRCA1) and mediator of DNA damage
checkpoint protein-1 (MDC1) [25].
Tyrosine 142 residue of H2A.X is constitutively phos-
phorylated and its subsequent dephosphorylation in
response to DNA damage may enhance MDC1 and
ATM recruitment to extend and maintain g-H2A.X
phosphorylation [52]. Phosphorylation and dephosphor-
ylation of H2A.X on its tyrosine 142 is regulated by the
tyrosine kinase WSTF (Williams-Beuren syndrome tran-
scription factor, also known as BAZ1B) and the protein
phosphatase EYA (Eyes Absent) [53,54]. Pre-existing
H2A.X tyrosine 142 phosphorylation by WSTF is critical
for DNA damage induced formation and retention of
g-H2A.X foci after DNA damage, while EYA removes
the tyrosine phosphorylation in response to DNA
damage. The presence of phosphorylated tyrosine 142
on H2A.X interferes with the MDC1 mediated recruit-
ment of DNA damage signaling and repair factors to
phosphorylated serine 139 residue of H2A.X[54].
The elimination of g-H2A.X at DNA damage sites is
required for appropriate DNA damage repair. In mam-
malian cells, dephosphorylation of serine 139 residue of
H2A.X is regulated by the protein phosphatase PP2A
and PP4 [55-57]. While PP4 dephosphorylates serine
139 of H2A.X in response to relatively low levels of
DNA damage that occur during DNA replication, higher
levels of damage might require both PP2A and PP4 to
eliminate g-H2AX [56]. In the absence of the catalytic
subunit of PP2A (PP2Ac), g-H2A.X foci persist and
DNA repair is impaired [55]. The effect of PP2A on
g-H2A.X is independent of ATM, ATR and DNA-PKcs.
PP4 dephosphorylates g-H2A.X both at the sites of
DNA damage and in undamaged chromatin, and deple-
tion of PP4 catalytic subunit (PP4C) causes prolonged
MDC1 retention at the sites of DNA lesions and results
in a prolonged checkpoint arrest [57].
MDC1 recognizes g-H2A.X and binds to it via its tan-
dem BRCA1 C-terminal (BRCT) domains [39]. This
recruitment of MDC1 to DSB sites further promotes the
accumulation and retention of active ATM and MRN
complexes to g-H2A.X containing chromatin surround-
ing the sites of DNA damage [38,39,58,59]. The MDC1
serine-aspartic acid-threonine (SDT) repeats near its N-
terminus, which are phosphorylated by Caseine Kinase 2
(CK2), interact with the N-terminal fork-head associated
(FHA) domain of NBS1 [60-63]. In undamaged cells,
MDC1 exists in a complex with MRN [60-63]; however,
following ATM activation, MDC1 and its interacting
MRN complex are recruited to g-H2A.X [60-63]. Inter-
estingly, while the N-terminus of NBS1 interacts with
MDC1, its C-terminus interacts with ATM. Hence,
MDC1 bridges the interaction of MRN to g-H2A.X and
ATM. The concentrated binding of ATM to MDC1 and
MRN further promotes the phosphorylation of H2A.X
and triggers the accumulation and retention at the sites
of DNA lesion of a number of factors essential for DSB
signaling including the RING finger proteins RNF8 and
RNF168, p53 binding protein 1 (53BP1) and BRCA1
[64].
These examples of phosphorylation/dephosphorylation
events highlight the importance of these processes in
the signaling of DSBs.
Roles of Ubiquitylation and SUMOylation in the Signal
Transduction of DSBs
Recent evidence have demonstrated major roles for ubi-
quitylation and Sumoylation in the signaling of DSBs
[65-68]. Post-translational modifications of proteins by
ubiquitin or small ubiquitin-like modifier (SUMO) are
ATP-dependent and are mediated by a sequential
enzyme cascade that involves ubiquitin or SUMO acti-
vating enzymes (E1), conjugation enzymes (E2) and pro-
tein ligases (E3) [69-71]. Ubiquitin is activated by the E1
enzyme and then a thioester linkage is formed between
the carboxyl terminal glycine of ubiquitin and the reac-
tive cysteine in E1. Subsequently, the ubiquitin is trans-
f e r r e df r o mE 1t ot h ea c t i v es i t ec y s t e i n eo ft h e
conjugation enzyme E2 through a trans-thioesterification
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that catalyzes an isopeptide bond between an ε-amino
group of a lysine residue in the substrate and the
C-terminal glycine of ubiquitin or SUMO, thus complet-
ing the post-translational modification.
E3 ligases govern the specificity of ubiquitylated sub-
strates and fall into four major groups; the HECT
(Homologous to the E6-AP Carboxyl Terminus) type
E3, the RING (Really Interesting New Gene) type E3,
the U-box type E3 and the A20-type C2/C2 zinc-finger
[72]. In the ubiquitin pathways, one E1 enzyme is shared
by all ubiquitin ligases, and the combination of 20 to 30
E2 enzymes and thousands of E3 ligases provide the
specificity of the ubiquitylated substrates [71]. Ubiquitin
is highly conserved among eukaryotes, and possesses
seven lysine (K) residues (K6, K11, K27, K29, K33, K48
and K63) that can be conjugated to other ubiquitins to
generate polyubiquitin chains and sometimes mixed-
linkage ubiquitin chains [73-76]. A number of ubiquitin
modifications including monoubiquitylation, multiubi-
quitylation and polyubiquitylation serve diverse func-
tions and cellular processes. Monoubiquitylation is
involved in a wide variety of cellular processes including
membrane protein transport, viral budding, protein loca-
lization and DNA damage responses [77-79]. While dif-
ferent types of ubiquitin linkages exist, K48 and K63-
linked polyubiquitin chains are the best characterized.
K48 mediated polyubiquitylation is known to target sub-
strates for proteasomal degradation [80] whereas K63-
linked polyubiquitylation is important for signal trans-
duction during immune responses, cell cycle and DNA
damage responses [81-84].
In the SUMOylation pathway, three mammalian
SUMO isoforms can be used for covalent modifications
of protein substrates. SUMO-1 conjugates only a single
SUMO moiety to a protein substrate, while SUMO-2 and
SUMO-3 which are similar, can form poly-SUMO chains.
SUMO isoforms are initially cleaved by SUMO-specific
proteases (SNEPs). Subsequently the cleaved SUMOs are
activated by the E1 enzyme that consists of SUMO1 acti-
vating enzyme subunit (SAE) 1 and 2 also known as
Uba2 and Aos1. SUMO is then transferred to the single
E2 enzyme UBC9 and subsequently ligated to the target
substrates by a few E3 ligases known as Protein Inhibitor
of Activated STAT (PIAS1, 2,3 and 4) [71,85].
Similar to other cellular processes, different ubiquitin
E3 ligases including RNF8, RNF168 and BRCA1/BARD1
have been demonstrated to play central roles in the
early signaling of DSBs (Figure 3). RNF8 and RNF168
function in collaboration with the E2 enzyme UBC13
[84], while the ligase BRCA1/BARD1 requires the E2
enzyme Ubch5c for its functions [86].
In response to DSBs, the three conserved threonine/
glutamine/X/phenylalanine (T-Q-X-F) clusters of MDC1
are phosphorylated by ATM [28,87-89]. The threonyl-
phosphorylated MDC1 interacts with the FHA domain
of the E3 ligase RNF8 and recruits it to DSB sites
[87-89]. In addition to its N-terminal FHA domain,
RNF8 also contains a C-terminal RING finger domain
important for its E3 ligase activities. Once RNF8 is
recruited by MDC1 to DSB sites, it collaborates with
UBC13 to mediate K63-linked ubiquitylation of the his-
tones H2A and H2A.X at the flanking sites of the DNA
lesion [90]. The histone H2A has been previously
demonstrated to be mono-ubiquitylated at K119 by the
E3 ligases RING1B (RING2/RNF2), RING1A/RING1
and 2A-HUB/hRUL138 [91-95]. In addition, 5 to 15% of
H2A is estimated to be constitutively ubiquitylated
[96,97].
RNF8 ubiquitylated H2A serves to recruit the E3
ligase RNF168 through its Motif Interacting with Ubi-
quitin 2 (MIU2) [98-100]. RNF168 and UBC13 mediate
K63-linked polyubiquitination of H2A and this polyubi-
quitylation has been proposed to modulate the chroma-
tin structure facilitating the recruitment of 53BP1 to
DSB sites. K63-linked polyubiquitylation of H2A also
serves to recruit Receptor-Associated Protein 80
(RAP80) via its tandem Ubiquitin Interaction Motifs
(UIMs) [101-105]. Subsequent to its interaction with
ubiquitylated histones, RAP80 facilitates the recruitment
to the DSB flanking sites of the BRCA1-A complex that
in addition to RAP80, contains BRCA1, BARD1,
ABRAXAS/FAM175A, BRCC3/BRCC36, BRE/BRCC45
and MERIT40/NBA1 [101].
Interestingly, the heterodimer BRCA1/BARD1 was
reported to form K6-linked ubiquitin chain during DNA
replication or repair [106,107]. BRCA1, in collaboration
with BARD1, has been shown to mediate ubiquitylation
of several substrates in vitro; however, it has been diffi-
cult to identify its in vivo ubiquitylation substrates.
g-tubulin [108], RPB8 [109], Topoisomerase IIa [110],
and CtIP [111] are among the established in vivo ubiqui-
tylation substrates for BRCA1.
While the importance of SUMOylation in DNA repair
and replication has been demonstrated earlier
[71,112-115], recent studies have highlighted its close
relationship with ubiquitylation during DSB signaling
[66,68]. The SUMO E3 ligases PIAS1 and PIAS4 were
shown to be recruited to DSBs and to be required for
the DSB-induced ubiquitylation mediated by RNF8 and
RNF168. PIAS4 is required for the accumulation of
RNF168 on DSB sites, through regulation of RNF8 and/
or RNF168 E3 ligase activities or through amplification
of protein-protein interactions. Furthermore, these stu-
dies demonstrated the SUMOylation of RAP80 and indi-
cated that RNF168 SUMOylation is mediated by PIAS4
or PIAS1 [67,116]. Interestingly, in response to DSBs,
PIAS4 also mediates SUMO1 modification of 53BP1 and
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mediated by PIAS1. These studies also indicated that
SUMOylation of BRCA1 is critical for its ubiquitin E3
ligase activity [66].
Thus, in addition to phosphorylation, increasing evi-
dence indicates the requirement for other posttransla-
tional modifications including ubiquitylation and
SUMOylation for the signaling of DSBs.
DNA Damage Response Proteins and Hereditary Human
Diseases
A number of hereditary human diseases/syndromes have
been associated with mutations that target genes
involved in the signaling of DSBs. Some of these genes
and the human diseases and syndromes associated with
their mutations are discussed here.
MRE11, RAD50 and NBS1
The MRN complex is recruited to the DNA damage site
and activates ATM. In contrast to Atm, knockout mouse
models for Mre11, Rad50 and Nbs1 are embryonic lethal
[117-119]. Hypomorphic mutant mice for Nbs1 or Mre11
exhibit increased radiosensitivity, defective cell cycle
checkpoints, chromosome instability and immunodefi-
ciency [120-123]. In contrast to Nbs1 or Mre11 hypo-
morphic mutant mice, Rad50 hypomorphic mutants
show partial embryonic lethality and exhibit progressive
hematopoietic stem cell failure without increased radio-
sensitivity or defective cell cycle checkpoints [124].
In human, NBS1 mutations have been associated with
the Nijmegen breakage syndrome (MIM #251260) char-
acterized by microcephaly, radiosensitivity, growth delay,
ovarian dysgenesis, immunodeficiency and marked can-
cer predisposition [125]. Patients with this syndrome are
prone to infectious diseases owing to humoral and cellu-
lar immune deficiency. At least 10 different NBS1 muta-
tions, most of them leading to truncated NBS1 proteins
or amino-acid substitutions that might affect NBS1 pro-
tein-protein interactions, have been reported for patients
with the Nijmegen breakage syndrome. These NBS1
mutants with truncations or amino-acid substitutions
are likely to retain partial NBS1 activities, thus explain-
ing the milder defects observed in these patients com-
pared to Nbs1 null mutation in mice that leads to
embryonic lethality [118,125].
Hypomorphic mutations of human MRE11 gene result
in ataxia telangiectagia like disorder (ATLD; MIM
#604391) characterized by cerebellar atrophy and radio-
sensitivity without marked immunodeficiency, cancer
predisposition or telangiectagia [126]. ATLD has slower
progression and is a milder condition compared to
ataxia telangiectagia (A-T) syndrome that associates
with ATM mutations. In contrast to NBS and A-T,
patients with ATLD have almost normal immune
responses. While the limited number of ATLD patients
does not allow determination of whether this syndrome
associates with increased cancer risk, Mre
ATLD1/ATLD1
mice exhibited impaired Atm functions but showed no
increased cancer susceptibility [121].
RAD50 deficiency (MIM #613078) was reported for a
patient with NBS-like disorder characterized by micro-
cephaly, growth retardation and radiosensitivity without
marked immunodeficiency or cancer predisposition
[127]. Cells from this patient exhibit cellular radio sensi-
tivity and defective activation of cell cycle checkpoints
in response to DSBs.
ATM
ATM plays important roles in the responses to induced
DSBs as well as to programmed DSBs generated during
V(D)J and meiotic recombinations. Atm deficiency in
mice results in defective activation of cell cycle check-
points, impaired rearrangement and expression of T-cell
receptors, reduced class switch recombination of immu-
noglobulins, sterility and tumorigenesis [22,128-133].
In human, mutations of ATM result in ataxia-telan-
giectagia (A-T; MIM #208900) characterized by progres-
sive cerebellar ataxia, oculocutaneous telangiectagia,
immune defects and lymphoid tumors [134]. In addition,
primary immunodeficiency, radiosensitivity and progres-
sive neurodegeneration are hallmarks of patients with
A-T. The cause of neurodegeneration in A-T patients
remains unknown. While, one-third of A-T patients
develop malignancies including lymphoid and breast
cancers, some A-T patients also develop insulin-resistant
diabetes and metabolic syndromes [25,135-137].
Somatic mutations of ATM have been also associated
with human cancers. Analysis of coding exons of 518
protein kinases in 210 different human cancers, indi-
cated that ATM gene ranked third in terms of mutation
frequency, behind Titin and BRAF (B-Raf proto-
oncogene serine/threonine-protein kinase) [138].
ATR
In humans, the autosomal recessive disorder known as
Seckel syndrome (MIM #210600) is associated with ATR
mutation [139,140]. Features of this syndrome include
microcephaly, developmental delay, mental retardation,
mild sensitivity to ultraviolet radiation, characteristic
facial features but no marked radiosensitivity and immu-
nodeficiency. ATR is a phosphoinositol 3-kinase-like
kinase that is activated by single-strand regions of DNA.
Several proteins are required for the ATR-signaling
response and defects of these proteins can result in
Seckel-like clinical features [141]. Thus, haploinsuffi-
ciency of replication protein A1 (RPA1) and replication
factor C2 (RFC2) has been associated with the Miller-
Dieker lissencephaly syndrome (MIM #247200) and the
William-Beuren syndrome (MIM #194050), respectively.
These syndromes are also characterized by microcephaly,
growth retardation and facial abnormality [142,143].
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embryonic lethality in mice [144]. Interestingly, a mouse
model carrying the ATR mutation (A2101G) associated
with the Seckel syndrome in patients, recapitulated the
symptoms of the human disease [145].
DNA-PKcs
DNA-PKcs-null mice are viable but exhibit radiosensitiv-
ity, immunodeficiency, and hyperplasia and dysplasia of
the intestinal mucosa. However, these mutant mice are
not growth retarded [146].
In humans, DNA-PKcs mutations result in radiosensi-
tive severe combined immunodeficiency (RS-SCID)
characterized by radiosensitivity and immunodeficiency
without microcephaly and mental retardation [147]. The
B-cell development defects of patients with this RS-
SCID are reminiscent of Artemis deficient SCID patients
and RAG (recombination activating genes) deficient
SCID patients [148,149]. No increased cancer predispo-
sition has been reported for patients with the RS-SCID
associated with DNA-PKcs mutations.
RNF168
The recently identified RIDDLE syndrome (MIM
#611943) has been associated with homozygous RNF168
mutations [99,150]. This syndrome is very rare as only
one patient has been identified to date. Characteristics
of the RIDDLE syndrome include radiosensitivity,
immunodeficiency, dysmorphic features and learning
difficulties. The identified RIDDLE patient has been
reported to have low concentrations of serum immuno-
globulin while the number of his peripheral lymphocytes
remained within normal ranges. Analysis of skin fibro-
blasts from this patient showed a mildly increased radio-
sensitivity, defective intra-S and G2/M phase
checkpoints, and impaired recruitment of 53BP1, RAP80
and BRCA1 to DSB sites. More patients with the RID-
DLE syndrome are needed to determine the spectrum of
pathologies associated with this syndrome and whether
it is associated with increased cancer predisposition.
Mouse models carrying mutations of Rnf8,a nE 3
ligase required for the recruitment of Rnf168 to sites of
DNA damage, have been reported. While no human
syndrome/disease have been reported yet to associate
with RNF8 mutations, Rnf8
-/- mice, similar to the RID-
DLE syndrome patient, suffer from defective IgH Class
Switch Recombination and are immunodeficient
[151,152]. Rnf8
-/- males also exhibit impaired spermato-
genesis and are infertile [151-153]. Remarkably, Rnf8
-/-
mice are growth retarded and display increased cancer
predisposition, demonstrating that Rnf8 is a novel
tumor suppressor [151]. Studies of mouse models for
Rnf168 mutations are required to determine whether
they reproduce characteristics of the RIDDLE syndrome
and whether, similar to Rnf8, Rnf168 plays a role in
cancer.
BRCA1
BRCA1 is important for a number of cellular functions
including activation of cell cycle checkpoints and repair
of DSBs through HR pathway [154]. Other functions
that have been ascribed to BRCA1 include transcription,
ubiquitylation, estrogen receptor signaling, and chroma-
tin remodeling [155-160].
Mutations of the tumor suppressor BRCA1 (MIM
#113705) predispose women for breast and ovarian can-
cer [161,162]. Typically, a germline mutation in one of
the BRCA1 alleles is inherited from one of the parents
and loss of heterozygosity (LOH) of the Wild-type
BRCA1 allele is required in order for tumors to develop.
Women with inherited inactivating mutation of BRCA1
gene have about a 65-80% lifetime risk of developing
breast cancer [163]. The familial breast cancer asso-
ciated with BRCA1 inactivation develops at younger
ages and is frequently bilateral compared to the sporadic
types of breast cancer. In addition, women with inher-
ited mutations of BRCA1 gene are also predisposed for
ovarian cancer with a lifetime risk about 37-62% com-
p a r e dt ol e s st h a n2 %f o rw o m e nt h a td on o tc a r r y
BRCA1 or BRCA2 mutations [163]. BRCA1 forms an E3
ligase with its partner BARD1 and its RING finger
domain is essential for this E3 ligase activity. Mutation
of cysteine 61 in the RING finger domain of BRCA1
(BRCA1C61G) has been observed in patients with the
familial breast cancer.
A remarkable therapeutic opportunity has been dis-
covered recently for cancer patients that carry mutations
of the familial breast cancer genes BRCA1 or BRCA2.
Both genes play important roles in the HR repair path-
way. Inactivation of either BRCA1 or BRCA2 has been
shown to drastically decreases HR activities [164,165].
Interestingly, recent studies indicated that inhibition of
the poly (ADP-ribose) polymerase (PARP) leads to syn-
thetic lethality of tumors deficient for either BRCA1 or
B R C A 2[ 1 6 6 - 1 6 9 ] .P A R P 1a n dP A R P 2f a c i l i t a t et h e
repair of SSBs by recruiting DNA repair proteins to the
damaged sites and promoting the restart of stalled repli-
cation forks [170]. In the absence of PARP activity, SSBs
can be converted to DSBs during replication. As BRCA1
and BRCA2 deficient tumors are defective in HR
mediated repair of DSBs, inactivation of PARP in these
tumors leads to collapsed replication folks, generation of
DSBs, cell cycle arrest and cell death [166,167]. Several
PARP inhibitors, including the third generation PARP
inhibitors with high potency and specificity, are in clini-
cal trial development worldwide [170]. There is cur-
rently great hope that these PARP inhibitors may
represent a great opportunity to improve the therapy for
BRCA1 and BRCA2 cancer patients.
Several mouse models for Brca1 mutation have been
reported[171]. While Brca1 null mutations lead to early
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mammary epithelial cells lead to mammary tumorigen-
esis [173,174]. In addition, inactivation of the Chk2-p53
pathway was found to synergize the development of
mammary tumors associated with Brca1 deficiency
[174].
Interestingly, recent studies demonstrated that inacti-
vation of 53bp1 rescued the proliferation defect and
hypersensitivity to DNA damaging agents, and partially
restored the HR defects of Brca1 deficient cells
[175,176]. Inactivation of 53bp1 suppressed the develop-
ment of mammary tumors in mice carrying hypo-
morphic Brca1 mutations (Brca1
Δ11/Δ11) [175]. 53BP1
expression was recently found frequently decreased in a
subset of basal-like/triple-negative breast cancers and in
BRCA1 or BRCA2 negative breast tumors [176]. Further
investigations are needed to clarify the precise effects of
53BP1 inactivation on the development of BRCA1 asso-
ciated breast cancers, the responses of these cancers to
therapies and the mechanisms and significance of the
reduced 53BP1 expression in breast tumors with BRCA1
or BRCA2 mutations.
Conclusion
Remarkable progress has been made over the past few
years regarding the signaling and repair mechanisms of
DNA double-strand breaks. Post-translational modifica-
tions have emerged as key factors that regulate these
processes. Although more studies are required to iden-
tify missing players in these repair/signaling pathways
and the mechanisms that control these processes, it is
likely that the considerable amount of knowledge accu-
mulated over the years will facilitate the development of
better therapies for human diseases including cancer.
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